**Background of TSC2 Antibody**
The TSC2 antibody targets the tuberous sclerosis complex 2 (TSC2) protein, encoded by the *TSC2* gene. TSC2. also known as tuberin, is a tumor suppressor that forms a heterodimeric complex with TSC1 (hamartin). This complex regulates the mTOR (mechanistic target of rapamycin) signaling pathway by acting as a GTPase-activating protein (GAP) for Rheb (Ras homolog enriched in brain), thereby inhibiting mTOR complex 1 (mTORC1) activity. Dysregulation of TSC2 due to mutations or loss of function leads to constitutive mTOR activation, contributing to tuberous sclerosis complex (TSC), a genetic disorder characterized by benign tumors in multiple organs, neurological deficits, and epilepsy.
TSC2 antibodies are widely used in research to study protein expression, localization, and post-translational modifications (e.g., phosphorylation at Ser939 or Thr1462) in cell and tissue samples. They are critical tools for investigating mTOR pathway dynamics, cellular growth, autophagy, and metabolic regulation. Commercially available TSC2 antibodies include polyclonal and monoclonal variants, often validated for applications like Western blotting, immunohistochemistry, and immunofluorescence.
In disease research, TSC2 antibodies help assess TSC2 expression loss in TSC-associated lesions or cancers and evaluate therapeutic responses to mTOR inhibitors. Challenges include ensuring antibody specificity due to homology between TSC2 and other proteins, necessitating validation via knockout cell lines or siRNA. Ongoing studies continue to refine TSC2 antibody utility in translational research and diagnostics.